A High Relaxivity Magnetic Resonance Imaging Contrast Agent Targeted to Serum Albumin
Stéphane Dumas(Epix Pharmaceuticals (United States)), Jeffrey S. Troughton(Epix Pharmaceuticals (United States)), Normand J. Cloutier(Epix Pharmaceuticals (United States)), Jaclyn M. Chasse(Epix Pharmaceuticals (United States)), Thomas J. McMurry(Epix Pharmaceuticals (United States)), Peter Caravan(Harvard University)
Cited by 12
Abstract
EP-647 is a serum albumin-targeted magnetic resonance imaging contrast agent comprising a GdDTPA (DTPA, diethylenetriaminepentaacetate) chelate for magnetic resonance signal generation linked via a phosphodiester to a substituted biphenyl for albumin targeting. Albumin binding and relaxivity are higher than the benchmark magnetic resonance angiographic agent MS-325. EP-647 binds primarily to a unique site on serum albumin that is different from the MS-325 site and the binding sites of other drugs.
Related Papers
No related papers found
Powered by citation graph analysis